Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Ken Powell

Ken Powell, President, Genesis Business DevelopmentPresident
Genesis Business Development
Member of the Healthcare Council

Ken Powell is the President of Genesis Business Development, a global healthcare consultancy. Mr. Powell has experience in the identification, acquisition, and commercialization of intellectual property, new businesses, and products in the medical device and clinical diagnostics market segments worldwide. He has extensive knowledge about emerging technologies, test kits, medical devices, clinical laboratory equipment, and molecular diagnostics market segments. Mr. Powell has held senior management positions with Becton Dickinson, Roche Diagnostics, Technicon, Armour Pharmaceuticals, and Upjohn Clinical Laboratory Procedures. He is conversant in all aspects of diagnostic and life sciences segments including product development, IP, valuation, technology assessment, manufacturing, finance, marketing, and sales. (This is me - Update Profile)


Employment History
2006 - present President
Genesis Business Development
1986 - 2006 Director of Business Development
Becton, Dickinson and Company
1984 - 1986 Director of Marketing
Revlon Healthcare
1982 - 1983 Senior Product Manager
Becton Dickinson Immunodiagnostics

GLG NewsSM Analyses by Ken Powell(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Infectious Diseases | 07-15-2008
Author: Ken Powell, President, Genesis Business Development

BD GeneOhm's recent CE Mark for its molecular diagnostic test for the rapid diagnosis of Clostridium difficile infection will likely intensify the competition between BD and Cepheid.  Both companies market tests for the $1 billion dollar Methicillin-Resistant Staphylococcus Aureus (MRSA)&...

Novel Test for Appendicitis | 07-15-2008
Author: Ken Powell, President, Genesis Business Development

A new test form AspenBio could revolutionalize the diagnosis of appendicitis.  Over 6 million patients present to Emergency Departments each year with abdominal pain, resulting in approximately 700,000 appendectomies.  Over $5 billion is spent each year in the US on CT scans, the currently...

Competitive Bidding Demo Repealed by House of Representatives | 07-11-2008
Author: Ken Powell, President, Genesis Business Development

The House of Representatives repealed the Centers for Medicare and Medicaid Services (CMS) authority to conduct a competitive bidding demonstration program for laboratory services.  Senate action is now required.

Datascope Benefits from Sale of Patient Monitoring Business | 06-05-2008
Analysis of: Datacsope stock soars on takeover tlaks | www.northjersey.com
Author: Ken Powell, President, Genesis Business Development

The sale of Datascope's (NASDAQ: DSCP) patient monitoring business earlier this year to Mindray Medical (NYSE: MR) has resulted in several acquisition offers from unnamed companies.  On Wednesday, Datascope's stock increased 11% in response to this news.   

View All GLG News SM Analyses by Ken Powell

GLG InstituteSM Seminars with Ken Powell(?)

 
Ken Powell has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare

Request a project with Ken Powell









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics